Marcin Frąckiewicz

Marcin Frąckiewicz is the CEO of TS2 Space and a longtime technology entrepreneur focused on telecommunications, satellite communications and digital innovation. A graduate of the Warsaw School of Economics (SGH), he writes about space technology, artificial intelligence and publicly traded technology companies. His analysis covers major market trends, emerging technologies and the businesses shaping the future of the global economy.

Titan Acquisition stock stays close to $10.40 with market watching $1.1B OpenPayd deal
··

Titan Acquisition stock stays close to $10.40 with market watching $1.1B OpenPayd deal

OpenPayd plans to go public on Nasdaq via a merger with Titan Acquisition Corp, valuing the fintech firm at $1.145 billion. Titan shares were steady at $10.40 in premarket trading Friday. The deal requires shareholder approval, regulatory clearance, and a minimum $130 million in proceeds. OpenPayd reported annualized recurring revenue above $85 million as of March 2026.
June 5, 2026
1st Source Rises on Regional Bank Rally; Eyes on Credit Ahead
·

1st Source Rises on Regional Bank Rally; Eyes on Credit Ahead

1st Source Corp. rose 2.7% to $74.65 late Thursday, lifting its market cap to about $1.81 billion as regional bank stocks advanced. The bank reported first-quarter net income of $39.96 million, up 6.5% from a year earlier, with diluted EPS at $1.63 and a raised dividend to 43 cents. Trading volume reached about 131,400 shares. The company increased its loan loss provision to $7.27 million amid a weaker economic outlook.
June 5, 2026
MicroAlgo Shares React to Quantum Simulator Update; Volumes Stay Light
·

MicroAlgo Shares React to Quantum Simulator Update; Volumes Stay Light

MicroAlgo Inc. rose 1.17% to $5.17 on Nasdaq after announcing new quantum-algorithm simulation technology, with trading volume well below average at 142,930 shares. The company did not disclose any customers or revenue targets for the new product. MicroAlgo’s market cap stood at $64.3 million at Thursday’s close. Broader tech shares were mixed, with the Nasdaq Composite down 0.09%.
June 4, 2026
BTC Development Stock Little Changed While Bitcoin Sells Off
·

BTC Development Stock Little Changed While Bitcoin Sells Off

BTC Development Corp. (Nasdaq) slipped 0.1% to $10.05 Thursday on thin volume, trading narrowly as bitcoin dropped 2.7% to around $63,485. The SPAC reported $257.3 million in trust and $1.7 million net income for Q1, with no operations started as of March 31. Shares remain near cash value, reflecting uncertainty over potential crypto-related deals.
June 4, 2026
enCore Energy Stock Edges Up as Uranium Project Update Puts Permits in Focus
·

enCore Energy Stock Edges Up as Uranium Project Update Puts Permits in Focus

enCore Energy shares rose 0.9% to $1.595 Thursday after the company finished the first phase of construction at its Upper Spring Creek uranium project in South Texas. The new ion-exchange plant can process 1,600 gallons per minute, with full capacity expected by late July. enCore reported Q1 net income of 3 cents per share and delivered 270,000 pounds of U3O8 at $67.78 per pound. Final permits for the project remain outstanding.
June 4, 2026
WTW Stock Jumps As AI, Dubai And Crypto Insurance Moves Pile Up
·

WTW Stock Jumps As AI, Dubai And Crypto Insurance Moves Pile Up

WTW shares climbed 2.7% to $257.86 in afternoon Nasdaq trading Thursday, rebounding from two days of losses. The move followed announcements of an AI workforce tool, a Dubai investment licence, and a digital-asset insurance acquisition. Peer insurance brokers also rose. WTW stock remains nearly 29% below its October 52-week high.
June 4, 2026
ImmunityBio Jumps Again as Traders Look to Anktiva News
·

ImmunityBio Jumps Again as Traders Look to Anktiva News

ImmunityBio filed a Form 144 on June 4 to sell 268,033 common shares valued at about $2.95 million. Shares rose 3.0% to $7.395 in afternoon trading, with volume near 5.8 million. The FDA set a January 6, 2027, decision date for an expanded Anktiva bladder-cancer label. First-quarter net product revenue reached $44.2 million, up 168% from a year ago.
June 4, 2026
Bank7 Stock Climbs as 27-Cent Dividend Lands: What BSVN Investors Need to Know
·

Bank7 Stock Climbs as 27-Cent Dividend Lands: What BSVN Investors Need to Know

Bank7 Corp shares rose 1.2% to $43.67 in thin Nasdaq trading Thursday as the company maintained its quarterly dividend at 27 cents a share, payable July 7 to holders as of June 19. First-quarter net income climbed 16.2% to $12.01 million, with total loans up 11.9% to $1.59 billion. The bank’s risk-based capital ratio stood at 15.96% on March 31. Bank7 warned that economic shifts could affect rates, credit quality, and loan demand.
June 4, 2026
Decent Holding Shares Pop Again As DXST Keeps Up Volatile Week
·

Decent Holding Shares Pop Again As DXST Keeps Up Volatile Week

Decent Holding Inc. surged 18.1% to $5.67 on Nasdaq after reporting about $8 million in preliminary revenue and adding 387 elderly-care sites in China from January to May. Chairman Dingxin Sun recently bought 400,000 Class B shares, raising his voting power to 90.5%. Nearly 1.58 million shares traded. The stock’s jump contrasted with declines in broader tech and waste-services sectors.
June 4, 2026
Boost Run Shares Fall After Filing Shows Growth, Spending Plans
·

Boost Run Shares Fall After Filing Shows Growth, Spending Plans

Boost Run shares fell 9.9% to $34.33 in early Nasdaq trading Thursday after the AI-infrastructure company released new guidance and quarterly results. Q1 revenue jumped 165% to $10.96 million, but net loss widened to $4.12 million. Annual recurring revenue reached $96 million as of April 30, with a $360 million contracted backlog. The company recently signed a $471.7 million, 36-month deal with Thinking Machines Lab.
June 4, 2026
Eikon Therapeutics Jumps Ahead of Biotech Peers
·

Eikon Therapeutics Jumps Ahead of Biotech Peers

Eikon Therapeutics shares rose 5.1% to $9.91 late Thursday morning, still about 45% below the $18 IPO price from February. The company completed enrollment for its Phase 2 lung cancer trial, reporting a 63.1% objective response rate. Eikon ended Q1 with $596 million in cash but posted an $83 million loss. Analyst price targets averaged $24.80, with most maintaining a “Buy” rating.
June 4, 2026
GreenPower Stock Slips as Tiny EV Bus Maker Faces a Real-World Test
·

GreenPower Stock Slips as Tiny EV Bus Maker Faces a Real-World Test

GreenPower Motor shares fell 0.89% to $1.11 in early Nasdaq trading Thursday, near the low end of a $1.10–$1.14 range, with no new order news. The company’s latest press release was a May 21 update on a heating system for its Nano BEAST bus. GreenPower’s market cap stood at about $5.5 million. Broader markets were mixed, with QQQ down 1.3% and Russell 2000 up 0.3%.
June 4, 2026
Quest Resource edges higher, focus turns to June vote
·

Quest Resource edges higher, focus turns to June vote

Quest Resource Holding Corp. shares rose 0.7% to $1.38 Thursday on light volume after new proxy filings highlighted potential dilution and board elections ahead of its June 30 annual meeting. First-quarter revenue fell 9.8% to $61.7 million, while net loss narrowed to $2.3 million. Director Audrey Dunning received 2,966 RSUs at $1.18 each, vesting in 2027. Notes payable stood at $63.4 million as of March 31.
June 4, 2026
Mereo BioPharma draws eyes ahead of Jefferies Healthcare talk
·

Mereo BioPharma draws eyes ahead of Jefferies Healthcare talk

Mereo BioPharma’s U.S. shares traded at $0.3342 in premarket Thursday, down $0.0104, as investors awaited CEO Denise Scots-Knight’s appearance at the Jefferies Global Healthcare Conference. The company’s setrusumab drug missed main fracture-reduction goals in Phase 3 trials but met secondary bone-density targets. Mereo reported $36.2 million in cash at March 31 and projects funding into mid-2027.
June 4, 2026
Psyence Biomedical draws attention premarket after filing on 30% stake
·

Psyence Biomedical draws attention premarket after filing on 30% stake

Psyence Biomedical shares rose to $3.95 in premarket trading after a Schedule 13D filing showed Psyence Labs Ltd. holds 30.05% of shares with full voting power. Psyence Labs may buy, sell, or hedge its stake. The company recently began dosing in a Phase IIb trial of NPX-5 psilocybin for cancer-related adjustment disorder. Psyence emphasizes control over its supply chain and GMP manufacturing for regulated psychedelics.
June 4, 2026
NIP Group Shares Spike as Bitcoin Mining Deal Gets Equity Update
·

NIP Group Shares Spike as Bitcoin Mining Deal Gets Equity Update

NIP Group Inc. issued 62.6 million Class A shares in a second closing for its bitcoin mining expansion, pushing its U.S.-traded ADSs up 5.3% to $0.4178 Wednesday. The company faces a Sept. 21, 2026, Nasdaq deadline to lift its share price above $1. NIP’s first-half 2025 net loss widened to $136.3 million on $61.2 million revenue. The mining deal’s long-stop date was extended to July 31, 2026.
June 4, 2026
1 … 13 14 15 16 17 … 236